Loading clinical trials...

UNKNOWNPHASE1

A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF

NCT01566578•Ennar Pharmaceuticals AF

View on ClinicalTrials.gov

Summary

Investigation of EGF-Receptor Downregulation by topical EGF (dermal cream) exposition.

Eligibility

Age

18 - 60 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Informed consent
•Mild to moderate psoriasis (all types) with active plaques on both body sides accessible for biopsy and self product application
•EGFR immunohistochemistry score \> 5
•Male
•Age 18-60 years

Exclusion Criteria

•Systemic psoriasis treatment 3 months prior and during the study
•Local psoriasis treatment on the investigational sites in the last 30 days or during the study
•Known hypersensitivity or allergy to the EGF containing product (Newskin) and/or to Vaseline/10% salicylic acid and/or to local anaesthetics of the amid type
•Known or suspected non-compliance to study protocol Coagulopathy or treatment with anticoagulants
•History of malignant disease Other clinically relevant concomitant disease state Participation in another investigational drug study in the last 30 days

Locations (1)

University Hospital Zurich, Dermatology Clinic

Zurich, Canton of Zurich, Switzerland

Key Dates

Start Date

April 1, 2012

Primary Completion Date

November 1, 2012

Completion Date

November 1, 2012

Last Updated

August 3, 2012

Enrollment

ESTIMATED participants

Conditions

Plaque Psoriasis

Interventions

Human recombinant epidermal growth factor

DRUG

Placebo cream

OTHER

Contacts

Michael Weisskopf, MD

CONTACT

michael.weisskopf@usz.ch

Rudi Neirinckx, MD

CONTACT

rudi_neirinckx@hotmail.com

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Plaque Psoriasis

View study

RECRUITINGPHASE2

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 3, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF

Inclusion Criteria

Exclusion Criteria

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis